Filing Analysis
Picard Medical, Inc. filed an 8-K to disclose an investor presentation published on August 19, 2026. The filing is intended for investor relations purposes and does not contain material financial changes or structural shifts.
📋 Key Facts
- Company published an investor presentation on August 19, 2026.
- The presentation is intended for investor relations and other purposes.
- The information in the presentation is not considered 'filed' for purposes of the Exchange Act liability.
Picard Medical, Inc. has received notice that NYSE American has accepted its Compliance Plan to address continued listing standard violations regarding stockholders' equity and recent losses. The company must meet specific milestones within an 18-month period to avoid delisting.
🚩 Red Flags
- Delisting risk: The company is currently under a Compliance Plan to avoid being removed from NYSE American.
- Negative Equity: Reported stockholders' deficit of $(1.4) million as of March 31, 2026.
- Consistent Losses: Operating losses in three of the last four fiscal years.
- Quarterly Review: The company is subject to ongoing quarterly reviews by the exchange to monitor compliance.
📋 Key Facts
- NYSE American accepted the Company's Compliance Plan on July 22, 2026.
- Non-compliance stems from Sections 1003(a)(i) and (ii) regarding stockholders' equity and recent losses.
- Reported stockholders' equity was $3.8 million as of December 31, 2025.
- Reported stockholders' deficit was $(1.4) million as of March 31, 2026.
- The company reported losses in three of its last four fiscal years ended December 31, 2025.
- The Company has a maximum period of 18 months from the original notice to regain compliance.
Picard Medical, Inc. has approved a 1-for-50 reverse stock split to consolidate its outstanding common shares. The transaction is scheduled to become effective on July 31, 2026, with new trading under the same symbol 'PMI' starting August 3, 2026.
🚩 Red Flags
- Significant reverse split ratio (1-for-50) often indicates a desperate attempt to boost share price to meet minimum exchange listing requirements.
- Potential for increased volatility and dilution of shareholder value through rounding/fractional share handling (though the filing states no fractional shares will be issued).
📋 Key Facts
- Reverse stock split ratio of 1-for-50.
- Effective date: July 31, 2026, at 5:00 PM ET.
- New trading commencement: August 3, 2026, on NYSE American.
- The par value per share remains $0.0001.
- A new CUSIP number (71953R 207) has been assigned to the common stock.
Picard Medical, Inc. held its Annual Meeting of Stockholders on July 17, 2026, where shareholders approved several key measures including a reverse stock split and the creation of Class B common stock with super-voting rights.
🚩 Red Flags
- Approval of a reverse stock split (ratio 1-for-15 to 1-for-50) is often used to boost share price to meet exchange listing requirements.
- Creation of Class B common stock with 20 votes per share significantly dilutes the voting power of common shareholders, concentrating control in preferred hands.
📋 Key Facts
- Shareholders approved an amendment to effectuate a reverse stock split at a ratio ranging from 1-for-15 to 1-for-50.
- Shareholders approved an amendment to designate Class B common stock, with each share carrying 20 votes per share.
- The election of directors (Richard Fang, Sam Van, Joe Xiao, and George Ye) was successful.
- Advisory votes on executive compensation frequency were approved for a 'one year' cycle.
- Ratification of MaloneBailey LLP as the independent registered public accounting firm for 2026 was completed.
Picard Medical, Inc. filed an amended 8-K (8-K/A) to replace a previously furnished press release regarding a pre-recorded presentation for the upcoming 2026 Annual Meeting of Stockholders. The amendment is intended solely to correct errors in the original Exhibit 99.1.
🚩 Red Flags
- Correction of previously furnished press release (potential clerical error or misstatement in original communication).
📋 Key Facts
- The filing is an amendment (8-K/A) to an Original Form 8-K filed on July 2, 2026.
- The purpose of the amendment is specifically to replace Exhibit 99.1 (a press release).
- The original press release concerned a pre-recorded presentation for the 2026 Annual Meeting of Stockholders scheduled for July 17, 2026.
- No other items or financial data in the Original Form 8-K were changed.
Picard Medical, Inc. filed an 8-K/A to amend a previous filing regarding the appointment of Dr. Joe Xiao to the Board of Directors. The amendment specifically corrects errors related to his committee appointments.
🚩 Red Flags
- Amendment required to correct previous regulatory filing (8-K/A) regarding board committee appointments.
📋 Key Facts
- Dr. Joe Xiao was appointed to the Board effective June 23, 2026.
- The filing is an Amendment (8-K/A) to correct previously reported committee assignments.
- Dr. Xiao entered into a standard indemnification agreement for directors.
- Compensation follows the company's existing policy as disclosed in the proxy statement filed June 15, 2026.
Picard Medical, Inc. filed an 8-K to provide a pre-recorded presentation regarding business performance and upcoming stockholder proposals. The filing serves as a supplementary disclosure ahead of the company's 2026 Annual Meeting of Stockholders.
📋 Key Facts
- The Company released a pre-recorded presentation covering business performance, product development, and manufacturing initiatives.
- The presentation includes details on proposals to be voted on at the 2026 Annual Meeting of Stockholders.
- The Annual Meeting of Stockholders is scheduled for July 17, 2026.
- The filing incorporates a transcript of the presentation as Exhibit 99.1.
Picard Medical, Inc. issued a press release and presentation in preparation for its upcoming 2026 Annual Meeting of Stockholders scheduled for July 17, 2026.
📋 Key Facts
- The Company released a pre-recorded presentation ahead of the 2026 Annual Meeting of Stockholders.
- Annual Meeting of Stockholders is scheduled for July 17, 2026.
- The filing was signed by Richard Fang, Interim Chief Executive Officer.
Picard Medical, Inc. announced the appointment of Dr. Joe Xiao to its Board of Directors and several key committees effective June 23, 2026.
📋 Key Facts
- Dr. Joe Xiao appointed to the Board of Directors on June 23, 2026.
- Term expires at the 2026 annual meeting of stockholders.
- Appointed to Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
- Compensation follows existing non-employee director policies as disclosed in the June 15, 2026 proxy statement.
Picard Medical, Inc. announced the departure of CEO Patrick NJ Schnegelsberg and his resignation from the Board effective June 18, 2026. Dr. Richard Fang has been appointed as Interim CEO to lead a planned leadership transition.
🚩 Red Flags
- Sudden leadership change in a micro-cap company can create short-term volatility and uncertainty regarding strategic direction.
📋 Key Facts
- Patrick NJ Schnegelsberg stepped down as CEO and Board member on June 18, 2026.
- The departure is described as part of a 'planned leadership transition' and not due to disagreements with the company.
- Dr. Richard Fang appointed as Interim CEO effective June 18, 2026.
- Interim CEO Dr. Fang will receive an annual salary of $400,000.
- Dr. Fang previously served as CEO from September 2021 to July 2023.
Picard Medical, Inc. announced the immediate termination of its Chief Financial Officer, Bernard Skaggs, on June 1, 2026. Simultaneously, the company appointed Georgina Smith as Chief Accounting Officer.
🚩 Red Flags
- Immediate termination of the CFO is a significant red flag for micro-cap companies, often signaling internal disputes, financial irregularities, or governance failures.
- The company has appointed a Chief Accounting Officer (CAO) but has not named a new Chief Financial Officer (CFO), leaving a critical executive vacancy.
📋 Key Facts
- Bernard Skaggs was terminated as CFO effective June 1, 2026.
- Georgina Smith was appointed as Chief Accounting Officer effective June 1, 2026.
- Georgina Smith previously served as Controller of SynCardia Systems, LLC (a company subsidiary) from January 2026 to May 2026.
- Ms. Smith is a CPA with previous experience at Rain Bird Corporation and Tucson Electric Power.
Picard Medical, Inc. filed an 8-K to furnish a press release containing a letter from Chairman Richard Fang to stockholders. The filing is specifically designated as 'furnished' rather than 'filed', reducing the legal liability associated with the content.
📋 Key Facts
- Date of report: May 29, 2026
- The filing includes a press release (Exhibit 99.1) featuring a letter from Chairman Richard Fang
- The company is an emerging growth company
- The report is furnished under Item 7.01 of the 8-K
Picard Medical, Inc. (PMI) received two separate NYSE American non-compliance notices — on May 8 and May 15, 2026 — for failing to meet continued listing standards related to minimum stockholders' equity. The company reported a stockholders' deficit of approximately $1.4 million as of March 31, 2026, and has incurred net losses in each of its three most recent fiscal years. PMI must submit a compliance plan by June 7, 2026, or face delisting procedures, with a final compliance deadline of November 8, 2027.
🚩 Red Flags
- Two separate NYSE American non-compliance notices received within 7 days (May 8 and May 15, 2026), indicating multiple listing standard failures simultaneously.
- Stockholders' deficit of approximately $1.4 million — not merely insufficient equity, but negative equity, falling $3.4 million short of the $2.0 million minimum requirement.
- Net losses reported in all three most recent fiscal years (FY2023, FY2024, FY2025), demonstrating a persistent inability to achieve profitability.
- '.BC' designation added to ticker symbol, publicly flagging non-compliance status to market participants.
- Delisting risk is real and time-bound: failure to submit or execute an acceptable plan by November 8, 2027 triggers formal delisting procedures.
- Multiple 8-K items (2.02, 3.01, 7.01) filed simultaneously, suggesting compounding operational and financial pressures.
- As an emerging growth company with negative equity, access to capital markets to remediate compliance may be severely constrained.
📋 Key Facts
- May 15, 2026: NYSE American issued notice of non-compliance with Section 1003(a)(i) of the NYSE American Company Guide, requiring at least $2.0 million in stockholders' equity for companies with recent losses.
- May 8, 2026: A prior notice was received for non-compliance with Section 1003(a)(ii) — a second, distinct listing standard violation.
- Reported stockholders' deficit of approximately $1.4 million as of March 31, 2026.
- Company has incurred losses from continuing operations and/or net losses in all three most recent fiscal years ended December 31, 2025.
- PMI must submit a compliance plan (the 'Plan') to NYSE American by June 7, 2026.
- If the Plan is accepted, compliance must be achieved by November 8, 2027, or delisting procedures will commence.
- Common stock continues to trade on NYSE American under 'PMI' but with added '.BC' designation (applied following the May 8 Notice), signaling non-compliance status.
- Filing covers Items 2.02, 3.01, 7.01, and 9.01 — four items in a single 8-K.
- Company is an emerging growth company incorporated in Delaware, headquartered in Tucson, AZ.
- CEO Patrick NJ Schnegelsberg signed the filing dated May 21, 2026.
Picard Medical, Inc. entered into a $5.0 million registered public offering at $0.30 per share and subsequently received a delisting notice from NYSE American for failing to maintain the minimum stockholders' equity requirement of $4.0 million.
🚩 Red Flags
- NYSE American delisting notice for equity deficiency
- Stockholders' equity of $3.8M is below the $4.0M exchange requirement
- Highly dilutive offering at a low price of $0.30 per share
- History of losses in three of the last four fiscal years
- Multiple 8-K items (1.01 and 3.01) filed simultaneously
📋 Key Facts
- On May 5, 2026, the Company agreed to a registered public offering of 16,666,667 shares and warrants at a combined price of $0.30 per unit.
- Gross proceeds from the offering are approximately $5.0 million before expenses.
- On May 8, 2026, NYSE American notified the Company of non-compliance with Section 1003(a)(ii) regarding stockholders' equity.
- Stockholders' equity was reported at $3.8 million as of December 31, 2025, below the $4.0 million requirement.
- The Company has incurred net losses in three of its four most recent fiscal years.
- A compliance plan must be submitted by June 7, 2026.
Picard Medical, Inc. entered into a Warrant Issuance and Exchange Agreement to reprice and increase the volume of outstanding warrants. The company is exchanging 7,009,346 warrants with a $2.675 exercise price for 10,000,000 new warrants with a significantly lower exercise price of $0.35.
🚩 Red Flags
- Massive reduction in warrant exercise price ($2.675 to $0.35) indicates a severe decline in company valuation since December 2025.
- Significant potential dilution of 10,000,000 shares.
- The repricing appears necessary to facilitate a new capital raise (S-1 offering), suggesting financial distress or lack of investor interest at higher prices.
📋 Key Facts
- Agreement dated May 5, 2026, with a holder of warrants originally issued in December 2025.
- Exercise price reduced from $2.675 to $0.35 per share, an 87% reduction.
- Number of shares issuable upon exercise increased from 7,009,346 to 10,000,000.
- The exchange is contingent upon the closing of a current registered offering on Form S-1 (File No. 333-295333).
- New warrants eliminate broad-based anti-dilution price protection and forced exercise provisions.
- The new warrants have a five-year term and include a 9.99% beneficial ownership limitation.
Picard Medical, Inc. announced preliminary unaudited top-line revenue results for its first fiscal quarter ended March 31, 2026. The disclosure was made via a press release furnished under Item 2.02.
📋 Key Facts
- The filing reports preliminary revenue for the quarter ended March 31, 2026.
- The information is furnished under Item 2.02 and is not deemed 'filed' for Section 18 purposes.
- The report was signed by CEO Patrick NJ Schnegelsberg on April 22, 2026.
- The company is classified as an emerging growth company.
Picard Medical, Inc. entered into a $555,555.56 convertible promissory note agreement with Quick Capital, LLC, receiving net proceeds of only $490,000 after discounts and fees. The agreement includes highly dilutive default provisions and restricts the company's ability to pay dividends while the debt is outstanding.
🚩 Red Flags
- High cost of capital: The company is paying effectively $65,555 in fees/discounts plus $66,666 in interest to net $490,000.
- Predatory conversion terms: The 25% discount to the lowest 10-day trading price upon default is characteristic of 'death spiral' financing.
- Aggressive repayment schedule: Monthly payments of ~$103k begin just three months after issuance for a nine-month note.
- Restrictive covenants: The company is prohibited from paying dividends or making distributions without buyer consent.
- Default multiplier: A 150%-200% penalty on principal upon default is extremely punitive.
📋 Key Facts
- Principal amount of the Note is $555,555.56 with an original issue discount (OID) of $55,555.56.
- Actual cash consideration received by the Company was $490,000 after OID and $10,000 in buyer expenses.
- A one-time interest charge of 12% ($66,666.67) was applied on the issuance date of April 7, 2026.
- The Company issued 80,128 shares of common stock as 'Origination Shares' to the buyer.
- Repayment consists of six equal monthly installments of $103,703.70 starting July 1, 2026.
- Upon default, the Note is convertible at 75% of the lowest trading price during the 10 trading days prior to conversion.
- Default penalties include the Note becoming due at 150% to 200% of the outstanding principal.
Picard Medical, Inc. held an earnings conference call on March 25, 2026, to discuss its financial and operating results for the fiscal year ended December 31, 2025. The company furnished the presentation materials used during the call as an exhibit to the filing.
📋 Key Facts
- Earnings call held on March 25, 2026
- Discussion focused on fiscal year ended December 31, 2025
- Exhibit 99.1 contains the earnings conference call presentation
- Company is an emerging growth company listed on NYSE American
Picard Medical, Inc. (PMI) reported its financial and operating results for the fiscal year ended December 31, 2025. The announcement was made via a press release on March 25, 2026, and furnished under Item 2.02.
📋 Key Facts
- Fiscal year ended December 31, 2025 results announced.
- Press release dated March 25, 2026, furnished as Exhibit 99.1.
- Registrant is an emerging growth company listed on NYSE American under ticker 'PMI'.
- The filing was signed by CEO Patrick NJ Schnegelsberg.
Picard Medical, Inc. announced its upcoming participation in the American College of Cardiology’s Annual Scientific Session & Expo in late March 2026.
📋 Key Facts
- The Company will participate in the American College of Cardiology’s Annual Scientific Session & Expo.
- The event is scheduled to take place from March 28 to March 30, 2026.
- The conference will be held in New Orleans, Louisiana.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
Picard Medical, Inc. issued a press release announcing a clinical milestone where its SynCardia Total Artificial Heart successfully sustained a patient for 119 days while awaiting a donor transplant.
📋 Key Facts
- The report was filed on March 19, 2026, under Item 7.01 Regulation FD Disclosure.
- The SynCardia Total Artificial Heart was used to bridge a patient to transplant for a duration of 119 days.
- The press release (Exhibit 99.1) details the successful outcome of the patient receiving a donor heart.
- The company is an emerging growth company listed on the NYSE American under the ticker PMI.
Picard Medical announced a clinical milestone where a patient was successfully sustained by the SynCardia Total Artificial Heart for over 1,600 days (more than four years) prior to a successful heart transplant. The disclosure highlights the long-term durability and efficacy of the company's core medical device technology.
📋 Key Facts
- A 29-year-old patient was implanted with the SynCardia Total Artificial Heart on September 2, 2021.
- The patient underwent a successful heart transplant on February 24, 2026.
- The device provided continuous support for over 1,600 days, demonstrating significant long-term reliability.
- The information was furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Picard Medical stockholders approved a 100% increase in authorized common shares and cleared the way for a major stock issuance to High Trail entities. The move allows the company to issue shares exceeding 20% of its current outstanding stock, signaling significant upcoming dilution.
🚩 Red Flags
- 100% increase in authorized common stock (from 150M to 300M) indicates massive potential dilution.
- Approval of >20% issuance to High Trail entities, which are frequently associated with structured, highly dilutive financing arrangements.
📋 Key Facts
- Authorized common stock increased from 150,000,000 to 300,000,000 shares.
- Stockholders approved the issuance of shares exceeding 20% of outstanding stock to HT Investments MA LLC and High Trail Special Situations LLC per NYSE American Rule 713.
- As of the February 6, 2026 record date, there were 73,701,176 shares of common stock outstanding.
- The special meeting was held on March 10, 2026, with approximately 57.16% of shares represented.
Picard Medical, Inc. announced that it will be featured in a television segment on BTV – Business Television, airing on FOX Business News on March 14, 2026. The broadcast will highlight the company's SynCardia Total Artificial Heart (TAH) and its development of next-generation artificial heart technology.
📋 Key Facts
- The company will be featured on BTV – Business Television on March 14, 2026, at 5:00 p.m. ET.
- The segment will air on FOX Business News.
- The focus of the media coverage is the SynCardia Total Artificial Heart (TAH) and future technology developments.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
Picard Medical, Inc. announced it will host an Annual Business Update webcast on March 25, 2026, to review its fiscal year and fourth quarter 2025 financial results.
📋 Key Facts
- The webcast is scheduled for March 25, 2026, at 4:30 p.m. Eastern Time.
- Management will discuss operational progress, commercial activity, and strategic priorities.
- The presentation will feature perspectives on the SynCardia Total Artificial Heart, including clinician views and a patient testimonial.
- The filing includes a press release as Exhibit 99.1.
Picard Medical, Inc. announced that its Vice President of Clinical Affairs, Dr. Andre Simon, will deliver three presentations at the Technology and Heart Failure Therapeutics 2026 conference in Boston.
📋 Key Facts
- The conference takes place from March 2-4, 2026, in Boston, Massachusetts.
- Dr. Andre Simon, VP of Clinical Affairs, is scheduled to give three separate presentations.
- The filing is a standard Item 7.01 Regulation FD disclosure to furnish a press release.
Picard Medical, Inc. announced its participation in the 'Hands-On Training Day' at the Technology and Heart Failure Therapeutics 2026 conference. The event is scheduled for March 1, 2026, in Boston, Massachusetts.
📋 Key Facts
- The company will participate in the Technology and Heart Failure Therapeutics 2026 conference.
- The specific event is a 'Hands-On Training Day' on March 1, 2026.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- A press release regarding the event was furnished as Exhibit 99.1.
Picard Medical, Inc. issued an 8-K to announce the launch of its 'Cruxx to MedTech Podcast,' a series focused on the SynCardia Total Artificial Heart and the Emperor device.
📋 Key Facts
- Announcement date: January 13, 2026
- Content focus: SynCardia Total Artificial Heart and the Emperor device
- Format: Launch of 'Cruxx to MedTech Podcast' series
Picard Medical, Inc. filed an 8-K to disclose the publication of a new investor presentation intended for investor relations and other purposes.
📋 Key Facts
- The company published an investor presentation on January 13, 2026.
- The presentation is intended for use in investor relations and other corporate communications.
- The filing includes Exhibit 99.1 containing the presentation.
Picard Medical, Inc. entered into a $15 million senior secured notes facility with an institutional investor, including warrants to purchase over 7 million shares of common stock. The agreement includes significant dilutive elements and requires the company to seek stockholder approval for share issuance and a massive increase in authorized shares.
🚩 Red Flags
- Significant potential dilution via 7 million+ warrants and PIK (payment-in-kind) share options.
- Requirement to increase authorized shares to 300 million suggests massive future dilution.
- Senior secured status: The company granted a first-priority security interest in substantially all tangible and intangible assets.
- High cash maintenance covenant ($4M) may constrain operational flexibility.
📋 Key Facts
- Entered into a securities purchase agreement on December 24, 2025.
- Issued $15,000,000 in senior secured notes due December 26, 2028, at 0.00% interest.
- Notes allow for monthly amortization payments in cash or shares (PIK).
- Issued warrants to purchase 7,009,346 shares of common stock at an exercise price of $2.675.
- The company must maintain a minimum cash balance of $4,000,000 while notes are outstanding.
- Requires stockholder approval for the issuance and to increase authorized shares to 300 million.
- Buyer has a right to participate in up to 25% of future financing for 18 months.
- WestPark Capital, Inc. acted as placement agent with a 7.5% cash fee plus warrants.
Picard Medical, Inc. filed an 8-K to announce that members of its management team will ring the opening bell at the New York Stock Exchange on December 18, 2025.
📋 Key Facts
- Management team scheduled to ring the NYSE opening bell.
- Filing date: December 18, 2025.
- The announcement is furnished via press release (Exhibit 99.1) and not filed as material non-public information.
Picard Medical, Inc. issued an 8-K to furnish a press release containing an update regarding the SynCardia Total Artificial Heart. The filing is made pursuant to Item 7.01 (Regulation FD Disclosure) and does not contain material financial changes or structural shifts.
📋 Key Facts
- Date of report: December 9, 2025
- The company issued a press release regarding an update on the SynCardia Total Artificial Heart.
- The filing is categorized under Item 7.01 (Regulation FD Disclosure).
- Information provided in Exhibit 99.1 is furnished but not 'filed' for purposes of liability under the Exchange Act.
Picard Medical, Inc. disclosed the presentation of in vitro data regarding its Emperor Total Artificial Heart at a medical conference in Vienna, Austria.
📋 Key Facts
- Presentation occurred on December 4, 2025, at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support.
- The presenter was Duffy Elmer, Engineering Project Manager.
- Data presented focused on in vitro performance of the Emperor Total Artificial Heart.
Picard Medical, Inc. announced that CEO Patrick NJ Schnegelsberg will present clinical data regarding the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt, Germany.
📋 Key Facts
- CEO Patrick NJ Schnegelsberg to present data on the Emperor Total Artificial Heart.
- Presentation scheduled for the CSI Focus D-HF (Device Therapies in Heart Failure) conference.
- Conference dates: December 5 and 6, 2025.
- Location: Frankfurt, Germany.
Picard Medical, Inc. entered into a $1,000,000 unsecured promissory note with Fang Family Fund, LLC, an affiliate of the Company's Chairman, Richard Fang. The funds are intended for short-term working capital and general corporate purposes to address immediate liquidity needs.
🚩 Red Flags
- Related-party transaction involving the Chairman of the Board
- Use of proceeds for 'short-term working capital' and 'liquidity management' often indicates immediate cash flow constraints
- Company explicitly states 'no assurances can be given regarding the timing or availability' of funds to repay the note from operations or future financing
📋 Key Facts
- Principal amount: $1,000,000
- Lender: Fang Family Fund, LLC (affiliate of Chairman Richard Fang)
- Interest rate: 6% per annum, compounded annually
- Maturity Date: November 27, 2026
- Purpose: General corporate purposes, working capital, and liquidity management
- Approval: Reviewed and approved by disinterested members of the Audit Committee and Board
Picard Medical, Inc. announced that Duffy Elmer will present in vitro data regarding the Emperor Total Artificial Heart at an upcoming international medical conference in Vienna.
📋 Key Facts
- Event: 31st Annual Meeting of the International Society for Mechanical Circulatory Support.
- Date of Event: December 1 to 4, 2025.
- Location: Vienna, Austria.
- Content: Presentation of in vitro data on the Emperor Total Artificial Heart by Duffy Elmer.
Picard Medical, Inc. announced that its wholly owned subsidiary, SynCardia Systems LLC, successfully completed the first in vivo implantations of the Emperor Total Artificial Heart.
📋 Key Facts
- Subsidiary SynCardia Systems LLC completed first in vivo implantations of the Emperor Total Artificial Heart.
- The announcement was made via press release on November 19, 2025.
- The event is reported under Item 7.01 (Regulation FD Disclosure).
Picard Medical, Inc. filed an 8-K to announce the release of its financial and operating results for the third quarter ended September 30, 2025.
📋 Key Facts
- The filing is a routine announcement of Q3 2025 financial and operating results.
- Results were announced via press release on November 14, 2025.
- The report was signed by CEO Patrick NJ Schnegelsberg.
Picard Medical, Inc. filed an 8-K to furnish a press release issued on October 24, 2025, regarding the recent volatility of its stock price.
🚩 Red Flags
- Explicit mention of 'volatility of its stock price' often suggests management is attempting to address market speculation or downward pressure on the share price.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- The company released a statement addressing stock price volatility on October 24, 2025.
- The press release is included as Exhibit 99.1.
Picard Medical, Inc. held a special meeting of stockholders on October 10, 2025, where shareholders approved an amendment to the company's 2021 Equity Incentive Plan. The amendment increases the available share pool and adds warrants as an issuable award type.
🚩 Red Flags
- Expansion of equity pool (potential dilution for existing shareholders).
📋 Key Facts
- Special Meeting held on October 10, 2025.
- Quorum was established with 54,377,330 shares represented (out of 73,701,176 outstanding).
- Stockholders approved an amendment to the 2021 Equity Incentive Plan.
- The amendment increases the aggregate number of shares available under the plan to 18,000,000 shares.
- Warrants are now included as a type of award issuable under the Amended Incentive Plan.
Picard Medical, Inc. announced the full exercise of an over-allotment option related to its recent Initial Public Offering (IPO). This resulted in the sale of additional shares and increased total gross proceeds from the offering.
📋 Key Facts
- The company completed a follow-on sale of 637,500 shares via the exercise of an over-allotment option on September 9, 2025.
- The over-allotment shares were sold at the IPO price of $4.00 per share.
- Total gross proceeds from the full IPO (including the over-allotment) amounted to approximately $19,550,000.
- A total of 4,887,500 shares were issued and sold as part of the complete offering process.
Picard Medical, Inc. successfully consummated its initial public offering (IPO) of 4,250,000 shares at $4.00 per share on September 2, 2025. The filing also notes the appointment of two new directors and the adoption of amended articles of incorporation and bylaws in connection with the IPO.
🚩 Red Flags
- Indemnification agreements for directors/officers (standard for IPOs but increases potential contingent liability).
📋 Key Facts
- Consummated IPO of 4,250,000 common shares on September 2, 2025.
- IPO pricing set at $4.00 per share.
- Underwriters included WestPark Capital, Inc., with a 30-day option to purchase an additional 637,500 shares.
- Appointed Sam Van and George Ye to the Board of Directors on August 12, 2025.
- Entered into indemnification agreements with directors and executive officers in connection with the IPO.
- Adopted Second Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws effective August 28, 2025.